CDC awards $215 million as part of Cancer Moonshot initiative revival
Reuters
Published Jun 08, 2022 03:39PM ET
Updated Jun 08, 2022 03:49PM ET
(Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) said it was awarding $215 million in first-year funding as part of reviving the erstwhile Obama administration's Cancer Moonshot initiative aimed at prevention and control of the disease.
The funding will be given to 86 recipients https://www.cdc.gov/cancer/dcpc/about/foa-dp22-2202, including various U.S. states as well as indigenous tribes such as Cherokee Nation, Kaw Nation of Oklahoma and Navajo Nation, among others.
It is part of an overall five-year investment plan worth $1.1 billion into three national programs to prevent and control cancer, the CDC said https://www.cdc.gov/media/releases/2022/p0608-cancer-award.html on Wednesday.
"This funding is a critical investment in support of President Biden's Cancer Moonshot initiative and our efforts to help ensure that everyone in the United States equitably benefits from the tools we have to detect and diagnose cancer," Health and Human Services Secretary Xavier Becerra said in the CDC statement.
U.S. President Joe Biden in February announced plans to reduce death rate from cancer by at least 50% over the next 25 years by speeding research and making more treatments available under the "Cancer Moonshot" initiative.
The initiative, launched in 2016, was led by Biden when he was vice-president.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.